Paper Review Records
All Paper Review Records
15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
27
days
Effector-to-target ratio as a translational bottleneck for CD33 T-cell engagers in acute myeloid leukemia: a quantitative reanalysis of AMG 330
AuthorsHamid Bellout
Affiliations1. Northern Illinois University, DeKalb, USA
89
days
Preclinical evaluation and mechanistic analysis of antitumor effects of the novel anti-CD147 antibody DS-1471a in liver cancer models
AuthorsHiroshi Yuita; Sadanori Watanabe; Jun Tsukada; Yoshikazu Johmura; Sae Aratani; Hirokazu Ishikawa; Ryuichi Nakamura; Miki Yokoyama; Mari Hashimoto; Hideo Yukinaga; Huynh The Hung; Makoto Nakanishi; Keisuke Fukuchi
Affiliations1. Translational Science Department II, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 2. Discovery Research Laboratories I, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 3. Division of Cancer and Senescence Biology, Cancer Research Institute, Institute for Frontier Science Initiative, Kanazawa University, Kanazawa, Japan; 4. Division of Cancer Cell Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; 5. Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan; 6. Translational Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 7. Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan; 8. Daiichi Sankyo Inc., Basking Ridge, USA; 9. Division of Cellular and Molecular Research, National Cancer Centre, Singapore, Singapore
76
days
A phase 1 study of PF-07260437, a B7-H4 × CD3 bispecific T-cell engager, in patients with advanced or metastatic breast, ovarian, and endometrial cancer
AuthorsFengting Yan; Marcia Cruz-Correa; Jennifer Specht; Edward Wenge Wang; Jinyu Lu; Hatem Soliman; Amy Jackson-Fisher; Szu-Yu Tang; Sibo Jiang; Christophe Le Corre; Meng Li; David Sommerhalder
Affiliations1. Swedish Cancer Institute, Seattle, USA; 2. Pan American Center for Oncology Trials, San Juan, USA; 3. Fred Hutchinson Cancer Center, Seattle, USA; 4. City of Hope Comprehensive Cancer Center, Duarte, USA; 5. Montefiore Einstein Comprehensive Cancer Center, Bronx, USA; 6. Moffitt Cancer Center, Tampa, USA; 7. Pfizer, San Diego, USA; 8. Pfizer, South San Francisco, USA; 9. NEXT Oncology, San Antonio, USA
136
days
Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancer
AuthorsJordi Rodon; Bert O’Neil; Christopher Lim; Natraj R. Ammakkanavar; Carlos Torrado; Kazuaki Matsuoka; Hiroshi Hirai; Akihiro Miura; Bailey Anderson; Leah Jin; Nanae Hangai; Amanda Long; Volker Wacheck; Lee Rosen
Affiliations1. MD Anderson Cancer Center, Houston, USA; 2. Community Health Network, Indianapolis, USA; 3. Division of Hematology-Oncology, UCLA, Los Angeles, USA; 4. Taiho Pharmaceutical Co. Ltd, Tokyo, Japan; 5. Taiho Oncology, Inc., Princeton, USA
88
days
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer
AuthorsKhobe Chandran; Christina Guo; Simon Pacey; Guillermo Villacampa; Ruth Matthews; Toby Prout; Joan Fernandes; Alison Turner; Mona Parmar; Ruth Riisnaes; Ana Ferreira; Suzanne Carreira; Claudia Bertan; Mateus Crespo; Ines Figueiredo; Wei Yuan; Denisa Bogdan; Florence Raynaud; Ruth Ruddle; Bianca Calì; Martino Maddalena; Arianna Calcinotto; Christina Yap; Adam Sharp; Andrea Alimonti; Johann De Bono; Alec Paschalis
Affiliations1. Institute of Cancer Research, London, UK; 2. The Royal Marsden NHS Foundation Trust, London, UK; 3. Department of Oncology, School of Clinical Medicine, University of Cambridge, Cambridge, UK; 4. Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Cambridge, UK; 5. Institute of Oncology Research (IOR), Bellinzona, Switzerland; 6. Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland; 7. Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; 8. Department of Health Sciences and Technology, Eidgenössische Technische Hochschule Zürich (ETH), Zurich, Switzerland; 9. Department of Medicine, University of Padova, Padua, Italy
38
days
Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors
AuthorsAlejandro Falcón; Gregory M. Cote; Javier Molina-Cerrillo; Axel Le Cesne; Pedro Rocha; Bruno Bockorny; David Paez; Javier Martin-Broto; Sant P. Chawla; Sara Martinez; Carmen Kahatt; Vicente Alfaro; Mariano Siguero; Javier Jimenez; Ana Custodio; Vicente Alonso-Orduña; Carlos López; Attila Kollár; Juan José Soto-Castillo; Luis Paz-Ares
Affiliations1. Medical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain; 2. Servicio de Oncología Médica, Hospital Universitario Virgen del Rocio, Seville, Spain; 3. Medical Oncology Department, Mass General Brigham Cancer Institute, Boston, USA; 4. Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain; 5. Medical Oncology Department, Institute Gustave Roussy, Villejuif, France; 6. Medical Oncology Department, Vall d’ Hebrón University Hospital, Barcelona, Spain; 7. Medical Oncology Department, Beth Israel Deaconess Medical Center, Boston, USA; 8. Medical Oncology Department, Sant Pau, CIBERER, Barcelona, Spain; 9. Medical Oncology Department, Fundación Jiménez Díaz University Hospital General de Villalba, and Instituto deInvestigacion Sanitaria Fundacion Jimenez Diaz (IIS/FJDUAM), Madrid, Spain; 10. Sarcoma Oncology Research Center, Santa Monica, USA; 11. Clinical R&D, Pharma Mar, Colmenar Viejo, Madrid, Spain; 12. Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; 13. Medical Oncology Department, Hospital Universitario Miguel Servet, Saragossa, Spain; 14. Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, UNICAN, Santander, Spain; 15. Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; 16. Medical Oncology Department, START Madrid CIOCC, Hospital Universitario HM Sanchinarro, Madrid, Spain; 17. Medical Oncology Department, Hospital Universitario, Madrid, Spain
34
days
Class-level DILI saturation and hERG-driven risk stratification among 2024–2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis
AuthorsNihan Küçük Yılmaz; Veysel Baskın
Affiliations1. Department of Medical Pharmacology, Faculty of Medicine, Yalova University, Yalova, Turkey; 2. Department of Medical Pharmacology, Faculty of Medicine, Hitit University, Çorum, Turkey
34
days
Hedgehog Inhibitor and Paclitaxel: A Phase I Trial of the Oral Hedgehog inhibitor Taladegib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumours
AuthorsRosalind Glasspool; Sarah Patricia Blagden; Michelle Lockley; Elaine McCartney; Carol Evans; Fiona Thomson; Jennifer Brown; Laura Spiers; Chantevy Pou; Liz-Anne Lewsley; Iain A. McNeish; T.R. Jeffry Evans
Affiliations1. Beatson West of Scotland Cancer Centre and School of Cancer Sciences, University of Glasgow, Glasgow, UK; 2. Early Phase Clinical Trials Unit, Churchill Hospital, Oxford University Hospitals, Oxford, UK; 3. Centre for Cancer Centre for Cancer Evolution, Barts Cancer Institute, Queen Mary University of London, London, UK; 4. Cancer Division, University College London Hospital, London, UK; 5. Glasgow Oncology Clinical Trials Unit, University of Glasgow, Glasgow, UK; 6. The Translational Pharmacology & Immunology Laboratory, School of Cancer Sciences, University of Glasgow, Glasgow, UK; 7. Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK
37
days
Prostate cancer cells’ growth is decreased by novel MYC inhibitors
AuthorsBita Nickkholgh; Joseph McGrath; Sivanandane Sittadjody; Jay Chauhan; Kwan-Young Jung; Steven Fletcher; K. C. Balaji
Affiliations1. Wake Forest Institute for Regenerative Medicine (WFIRM), Wake Forest University School of Medicine, Winston-Salem, USA; 2. Department of Physiology-Pharmacology, Wake Forest University School of Medicine, Winston-Salem, USA; 3. Department of Urology, University of FL College of Medicine – Jacksonville, Jacksonville, USA; 4. Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, USA
126
days
Spatial blueprint of colorectal cancer identifies Hypoxic CAF program that orchestrates Go-or-Grow decisions and predicts outcomes
AuthorsMingkai Chen; Juan Yang; Jin Wang; Guangrun Du; Lida Zhang
Affiliations1. Department of Gastroenterology, Fuwai Central China Cardiovascular Hospital, Zhengzhou, China; 2. Department of Gastroenterology, Zhengzhou Yihe Hospital Affiliated to Henan University, Zhengzhou, China
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days